NCT02518945View on ClinicalTrials.gov

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Dapagliflozin or Farxiga is a SGLT-2 inhibitor

DRUG

Insulin

DRUG

Liraglutide

Victoza(Liraglutide) is a GLP-1 agent.

DRUG

Dapagliflozin placebo

Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin

Trial Locations (1)

14215

ECMC Ambulatory Center, 3rd Floor, Buffalo

All Listed Sponsors
lead

University at Buffalo

OTHER

NCT02518945 - Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter